Offer Update

29 April 2005 Not for release, publication or distribution in, into or from Australia, Canada, Japan or the United States Recommended Offer by UBS Limited on behalf of Microgen plc for AttentiV Systems Group plc Additional Irrevocable Undertaking Further to the announcement released on 28 April 2005 by Microgen plc (' Microgen') regarding its agreed terms of a recommended offer for the entire issued and to be issued share capital of AttentiV Systems Group plc ('AttentiV ') ('Offer'), Microgen announces that it has since received an irrevocable undertaking from Unicorn Asset Management Limited ('Unicorn') to accept the Offer in respect of 1,400,100 AttentiV shares held by Unicorn, representing approximately 2.3 per cent. of AttentiV's existing issued share capital. The irrevocable undertaking provided by Unicorn will cease to be binding only in the event of an announcement of a third party offer representing at least a 10 per cent. premium to the value of the Offer. Microgen has now received irrevocable undertakings from AttentiV shareholders to accept (or use all reasonable endeavours to procure the acceptance of) the Offer in respect of 23,335,857 AttentiV shares, representing approximately 38.5 per cent. of AttentiV's existing issued share capital. In addition to the irrevocable undertakings, Microgen has received non-binding letters of intent to accept the Offer in respect of a total of 9,663,475 AttentiV shares representing approximately 16.0 per cent. of the existing issued share capital of Microgen. In aggregate, therefore, Microgen has received irrevocable undertakings and non-binding letters of intent to accept the Offer in respect of 32,999,332 AttentiV shares, representing approximately 54.5 per cent. of the existing issued AttentiV shares. Enquiries: UBS Investment Bank (Financial Adviser to Microgen) John Woolland Nick Adams 020 7567 8000 Financial Dynamics (PR to Microgen) Giles Sanderson Ben Way 020 7831 3113 Hawkpoint (Financial Adviser to AttentiV) Paul Baines Graham Paton 020 7665 4500 UBS Investment Bank is acting exclusively for Microgen in connection with the Offer and no one else and will not be responsible to anyone other than Microgen for providing the protections afforded to clients of UBS Investment Bank or for providing advice in relation to the Offer. Hawkpoint, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively as financial adviser to AttentiV in connection with the Offer and no one else and will not be responsible to anyone other than AttentiV for providing the protections afforded to clients of Hawkpoint nor for providing advice in relation to the Offer. This announcement does not constitute an offer or invitation to purchase or subscribe for securities.
UK 100

Latest directors dealings